Axzyb 1MG Tablet, containing the active ingredient Axitinib, is a targeted therapy medication primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. Each tablet contains 1 mg of Axitinib, which is designed to inhibit tumor growth by blocking specific proteins that promote cancer cell proliferation and survival. This medication is typically prescribed for patients who have previously undergone treatment with other therapies, such as sunitinib or cytokines, and have not achieved satisfactory results. Axzyb is available in a pack of 60 tablets, making it convenient for long-term treatment regimens. As a potent tyrosine kinase inhibitor, Axitinib works by interfering with the vascular endothelial growth factor (VEGF) signaling pathway, which is crucial for tumor blood vessel formation. This mechanism helps to starve tumors of the nutrients and oxygen they need to grow, thereby slowing down or halting cancer progression.